表紙
市場調查報告書

人類用結合疫苗的全球市場:2020年-2024年

Global Human Combination Vaccines Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 953802
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
人類用結合疫苗的全球市場:2020年-2024年 Global Human Combination Vaccines Market 2020-2024
出版日期: 2020年07月30日內容資訊: 英文 120 Pages
簡介

全球人類用結合疫苗的市場規模在2020年∼2024年間,預測將成長到49億8,000萬美元,年複合成長率預測將為9%。市場擴大的原動力是兒童人口的增加,抗病毒藥物抗藥性問題的嚴重化,感染疾病的病例增加等要素。

本報告提供全球人類用結合疫苗市場調查,提供各類型分析,客戶與各地區市場分析,各供應商的勢力圖與簡介等資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場情況

各類型市場

  • 市場定義
  • 市場區隔
  • 市場區隔分析
  • 2019年的市場規模
  • 各類型比較
  • 不活化疫苗
  • 減毒活病毒疫苗

波特的五力分析

客戶形勢

各地區情勢

  • 北美
  • 歐洲
  • 亞洲

各類型的市場分析

  • 各類型比較
  • 主要國家
  • 各地區市場機會
  • 不活化疫苗
  • 減毒活病毒疫苗
  • 市場牽引角色-需求主導成長
  • 市場機會
  • 市場課題
  • 市場趨勢

客戶形勢

各地區情勢

  • 北美
  • 歐洲
  • 亞洲
  • 其他

各供應商的勢力圖

  • 各供應商的勢力圖
  • 各地區市場
  • 創新的動向
  • 各地區比較

各供應商分析

  • 交易廠商
  • 各供應商的定位

各供應商的勢力圖

  • 業者情勢
  • 創新的動向

供應商分析

  • 成為對象的供應商
  • 各供應商的定位
  • Cadila Healthcare Ltd.
  • CSL Ltd.
  • Daiichi Sankyo Co. Ltd.
  • GlaxoSmithKline Plc
  • MassBiologics
  • Meiji Holdings Co. Ltd.
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.

附錄

目錄
Product Code: IRTNTR44620

Technavio has been monitoring the human combination vaccines market and it is poised to grow by $ 4.98 bn during 2020-2024 progressing at a CAGR of 9% during the forecast period. Our reports on human combination vaccines market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increase in the pediatric population, increasing antiviral drug resistance and rise in cases of infectious diseases.

The human combination vaccines market analysis includes type segment and geographic landscape.

Technavio's ‘human combination vaccines market ’ is segmented as below:

By Type:

  • Inactivated vaccine
  • Live attenuated vaccine

By Geographic Landscape:

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the growing interest in R&D of new vaccines as one of the prime reasons driving the human combination vaccines market growth during the next few years. Also, the presence of government-sponsored programs and threats from bioterrorism will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our human combination vaccines market covers the following areas:

  • Human combination vaccines market sizing
  • Human combination vaccines market forecast
  • Human combination vaccines market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human combination vaccines market vendors that include Cadila Healthcare Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, MassBiologics, Meiji Holdings Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Sanofi, and Takeda Pharmaceutical Co. Ltd. Also, the human combination vaccines market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Threat of substitutes
  • Market ecosystem
  • Threat of rivalry
  • Value chain analysis

Market Sizing

  • Market condition

Market Segmentation by Type

  • Market definition
  • Market segments
  • Market segment analysis
  • Market size 2019
  • Comparison by Type
  • Inactivated vaccine - Market size and forecast 2019-2024
  • Market outlook: Forecast for 2019 - 2024
  • Live attenuated vaccine - Market size and forecast 2019-2024

Five Forces Analysis

  • Market opportunity by Type
  • Five force analysis
  • Bargaining power of buyers

Customer landscape

Geographic Landscape

  • Bargaining power of suppliers
  • Threat of new entrants
  • Geographic segmentation
  • Geographic comparison
  • Threat of substitutes
  • North America - Market size and forecast 2019-2024
  • Threat of rivalry
  • Europe - Market size and forecast 2019-2024
  • Market condition
  • Asia - Market size and forecast 2019-2024

Market Segmentation by Type

  • ROW - Market size and forecast 2019-2024
  • Market segments
  • Comparison by Type
  • Key leading countries
  • Market opportunity by geography
  • Inactivated vaccine - Market size and forecast 2019-2024
  • Live attenuated vaccine - Market size and forecast 2019-2024
  • Market drivers - Demand led growth
  • Market opportunity by Type
  • Market challenges
  • Market trends

Customer landscape

Geographic Landscape

Vendor Landscape

  • Vendor landscape
  • Geographic segmentation
  • Landscape disruption
  • Geographic comparison

Vendor Analysis

  • North America - Market size and forecast 2019-2024
  • Vendors covered
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • Market positioning of vendors
  • Cadila Healthcare Ltd.
  • ROW - Market size and forecast 2019-2024
  • CSL Ltd.
  • Key leading countries
  • Daiichi Sankyo Co. Ltd.
  • Market opportunity by geography
  • GlaxoSmithKline Plc
  • Market drivers - Demand led growth
  • MassBiologics
  • Market challenges
  • Meiji Holdings Co. Ltd.
  • Market trends

Vendor Landscape

  • Merck & Co. Inc.
  • Vendor landscape
  • Mitsubishi Tanabe Pharma Corp.
  • Landscape disruption
  • Sanofi

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Scope of the report
  • Currency conversion rates for US$
  • Cadila Healthcare Ltd.
  • Research methodology
  • CSL Ltd.
  • List of abbreviations
  • Daiichi Sankyo Co. Ltd.
  • GlaxoSmithKline Plc
  • MassBiologics
  • Meiji Holdings Co. Ltd.
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Type - Market share 2019-2024 (%)
  • 22: Comparison by Type
  • 23: Inactivated vaccine - Market size and forecast 2019-2024 ($ million)
  • 24: Inactivated vaccine - Year-over-year growth 2019-2024 (%)
  • 25: Live attenuated vaccine - Market size and forecast 2019-2024 ($ million)
  • 26: Live attenuated vaccine - Year-over-year growth 2019-2024 (%)
  • 27: Market opportunity by Type
  • 28: Customer landscape
  • 29: Market share by geography 2019-2024 (%)
  • 30: Geographic comparison
  • 31: North America - Market size and forecast 2019-2024 ($ million)
  • 32: North America - Year-over-year growth 2019-2024 (%)
  • 33: Europe - Market size and forecast 2019-2024 ($ million)
  • 34: Europe - Year-over-year growth 2019-2024 (%)
  • 35: Asia - Market size and forecast 2019-2024 ($ million)
  • 36: Asia - Year-over-year growth 2019-2024 (%)
  • 37: ROW - Market size and forecast 2019-2024 ($ million)
  • 38: ROW - Year-over-year growth 2019-2024 (%)
  • 39: Key leading countries
  • 40: Market opportunity by geography ($ million)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: Cadila Healthcare Ltd. - Overview
  • 48: Cadila Healthcare Ltd. - Business segments
  • 49: Cadila Healthcare Ltd. - Key offerings
  • 50: Cadila Healthcare Ltd. - Key customers
  • 51: Cadila Healthcare Ltd. - Segment focus
  • 52: CSL Ltd. - Overview
  • 53: CSL Ltd. - Business segments
  • 54: CSL Ltd. - Key offerings
  • 55: CSL Ltd. - Key customers
  • 56: CSL Ltd. - Segment focus
  • 57: Daiichi Sankyo Co. Ltd. - Overview
  • 58: Daiichi Sankyo Co. Ltd. - Business segments
  • 59: Daiichi Sankyo Co. Ltd. - Key offerings
  • 60: Daiichi Sankyo Co. Ltd. - Key customers
  • 61: Daiichi Sankyo Co. Ltd. - Segment focus
  • 62: GlaxoSmithKline Plc - Overview
  • 63: GlaxoSmithKline Plc - Business segments
  • 64: GlaxoSmithKline Plc - Key offerings
  • 65: GlaxoSmithKline Plc - Key customers
  • 66: GlaxoSmithKline Plc - Segment focus
  • 67: MassBiologics - Overview
  • 68: MassBiologics - Product and service
  • 69: MassBiologics - Key offerings
  • 70: MassBiologics - Key customers
  • 71: MassBiologics - Segment focus
  • 72: Meiji Holdings Co. Ltd. - Overview
  • 73: Meiji Holdings Co. Ltd. - Business segments
  • 74: Meiji Holdings Co. Ltd. - Key offerings
  • 75: Meiji Holdings Co. Ltd. - Key customers
  • 76: Meiji Holdings Co. Ltd. - Segment focus
  • 77: Merck & Co. Inc. - Overview
  • 78: Merck & Co. Inc. - Business segments
  • 79: Merck & Co. Inc. - Key offerings
  • 80: Merck & Co. Inc. - Key customers
  • 81: Merck & Co. Inc. - Segment focus
  • 82: Mitsubishi Tanabe Pharma Corp. - Overview
  • 83: Mitsubishi Tanabe Pharma Corp. - Business segments
  • 84: Mitsubishi Tanabe Pharma Corp. - Key offerings
  • 85: Mitsubishi Tanabe Pharma Corp. - Key customers
  • 86: Mitsubishi Tanabe Pharma Corp. - Segment focus
  • 87: Sanofi - Overview
  • 88: Sanofi - Business segments
  • 89: Sanofi - Key offerings
  • 90: Sanofi - Key customers
  • 91: Sanofi - Segment focus
  • 92: Takeda Pharmaceutical Co. Ltd. - Overview
  • 93: Takeda Pharmaceutical Co. Ltd. - Product and service
  • 94: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 95: Takeda Pharmaceutical Co. Ltd. - Key customers
  • 96: Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 97: Currency conversion rates for US$
  • 98: Research Methodology
  • 99: Validation techniques employed for market sizing
  • 100: Information sources
  • 101: List of abbreviations